

July 25, 2024

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

Sub: Intimation regarding re-appointment of Managing Director and CEO

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”), we wish to inform you that based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company in its meeting held today has approved the re-appointment of Dr. Yasir Rawjee (DIN 01965174) as Managing Director and CEO of the Company for a term of 5 years with effect from August 13, 2024 to August 12, 2029 subject to approval of the shareholders.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular dated July 11, 2023 and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above re-appointment is given in Annexure enclosed herewith.

This information will also be available on the website of the Company at www.glenmarklifesciences.com

You are requested to take the same on record.

Thanking You.
Yours faithfully,
For Glenmark Life Sciences Limited

Rudalf Corriea
Company Secretary and Compliance Officer
Encl: As above

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com

Annexure**Details under Regulation 30 of SEBI Listing Regulations**

Sr. No.	Particulars	Details
1.	Name & Designation of Director	Dr. Yasir Rawjee (Managing Director and CEO)
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment
3.	Date of Appointment/ reappointment / cessation (as applicable) and term of appointment /reappointment	Re-appointed as Managing Director and CEO of the Company for a term of 5 years with effect from August 13, 2024 to August 12, 2029 subject to approval of the shareholders.
4.	Brief Profile	Dr. Yasir Rawjee is the Managing Director and CEO of the Company. He has been associated with the Company since May, 2019. He leads the overall operations of the Company and is responsible for the overall business strategy of the Company. He holds a bachelor's degree in science from St. Xavier's College, University of Bombay and a bachelor's degree in science (technology) from University Department of Chemical Technology, University of Bombay. He also holds a PhD from Texas A&M University, U.S.A. He has over three decades of industry work experience and prior to joining the Company, he was the head of global API operations at Mylan Laboratories Limited. He was also the Senior Vice President at Matrix Laboratories Limited.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Dr. Yasir Rawjee is not related to any of the Directors of the Company.
6.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018- 19 and the National Stock Exchange of India Ltd with ref. no. NSE/CML/2018/24, dated 20 June 2018	Dr. Yasir Rawjee is not debarred from holding the office of director pursuant to any SEBI order or any other authority.

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com